Life sciences companies face ongoing pricing and cost pressures, driving a focus on operating performance within an evolving regulatory and risk environment. Yet opportunities may lie in the adoption of new business models enabled by scientific and technological advances.
Tackling digital transformation How biopharma companies can realize the power of digital and prepare for a new reality
Return on capital performance in life sciences and health care How have organizations performed and where are best bets going forward?
Articles & media